Hematologic (Blood)

NRG – S2209 at https://www.clinicaltrials.gov/study/NCT05561387

A Phase III randomized trial for newly diagnosed multiple myeloma (NDMM) patients considered frail or in a subset of “intermediate fit,” comparing upfront three-drug induction regimens followed by double- or single-agent maintenance

Cancer Type: Multiple myeloma, newly diagnosed

Principal Investigator: Dr. Ryan Devine

Please contact Clinical Trials Office for more details: 561-263-5791